Medtronic (NYSE:MDT – Free Report) had its price objective decreased by Truist Financial from $90.00 to $88.00 in a research note published on Friday, Benzinga reports. Truist Financial currently has a hold rating on the medical technology company’s stock. A number of other equities analysts have also recently issued reports on MDT. Royal Bank of […]

Related Keywords

Canada , Michael Marinaro , Royal Bank , Needham Company , First City Capital Management Inc , Medtronic Company Profile , Cetera Advisors , Medtronic , Cetera Advisor Networks , Community Trust Investment Co , Free Report , Truist Financial , Get Free Report , Advisor Networks , City Capital Management , Cardiovascular Portfolio , Medtronic Daily ,